跳轉至內容
Merck
  • LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.

LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.

Nature communications (2019-12-06)
Daniel Ysselstein, Maria Nguyen, Tiffany J Young, Alex Severino, Michael Schwake, Kalpana Merchant, Dimitri Krainc
摘要

Mutations in LRRK2 and GBA1 are common genetic risk factors for Parkinson's disease (PD) and major efforts are underway to develop new therapeutics that target LRRK2 or glucocerebrosidase (GCase). Here we describe a mechanistic and therapeutic convergence of LRRK2 and GCase in neurons derived from patients with PD. We find that GCase activity was reduced in dopaminergic (DA) neurons derived from PD patients with LRRK2 mutations. Inhibition of LRRK2 kinase activity results in increased GCase activity in DA neurons with either LRRK2 or GBA1 mutations. This increase is sufficient to partially rescue accumulation of oxidized dopamine and alpha-synuclein in PD patient neurons. We have identified the LRRK2 substrate Rab10 as a key mediator of LRRK2 regulation of GCase activity. Together, these results suggest an important role of mutant LRRK2 as a negative regulator of lysosomal GCase activity.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
抗 α-微管蛋白单克隆抗体 小鼠抗, ascites fluid, clone B-5-1-2
Sigma-Aldrich
Anti-GAPDH,克隆6C5, clone 6C5, Chemicon®, from mouse
Sigma-Aldrich
Venor GeM 支原体检测试剂盒,基于 PCR
Sigma-Aldrich
单克隆抗-MAP2 小鼠抗, clone HM-2, ascites fluid
Sigma-Aldrich
抗 葡萄糖脑苷脂酶(C 端) 兔抗, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
兔抗酪氨酸羟化酶多克隆抗体, liquid, Calbiochem®